drugset / Trial / NCT07244003

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

NCT07244003

Phase 4 Recruiting 430 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.

Timeline

Start
2025-03-29
Primary completion
2027-12-31
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Other
Subject ganagliflozin Unknown 50 mg Oral
Background Metformin Small molecule